Prior to the February 3, 2009 Food and Drug Administration advisory panel hearing on prasugrel (Lilly/Daiichi Sankyo), the drug's sponsor called the agency to question the inclusion of Dr Sanjay Kaul (Cedars-Sinai Medical Center, Los Angeles, CA) on the Cardiovascular and Renal Drugs Advisory Committee, heartwire has learned.
In an interview, FDA officials insisted that the call from Lilly had no bearing on their decision to exclude Kaul but acknowledged "mistakes" were made.
Much much more here.
No comments:
Post a Comment